OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)

被引:3
作者
Robson, Mark E. [1 ]
Im, Seock-Ah [2 ]
Senkus, Elzbieta [3 ]
Xu, Binghe [4 ]
Domchek, Susan [5 ]
Masuda, Norikazu [6 ]
Delaloge, Suzette [7 ]
Li, Wei [8 ]
Tung, Nadine [9 ]
Armstrong, Anne [10 ]
Wu, Wenting [11 ]
Goessl, Carsten [11 ]
Runswick, Sarah [12 ]
Conte, Pierfranco [13 ,14 ]
机构
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Med Univ Gdansk, Gdansk, Poland
[4] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
[5] Univ Penn, Basser Ctr, Philadelphia, PA 19104 USA
[6] Natl Hosp Org, Osaka Natl Hosp, Osaka, Japan
[7] Inst Gustave Roussy, Villejuif, France
[8] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China
[9] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA
[10] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[11] AstraZeneca, Gaithersburg, MD USA
[12] AstraZeneca, Macclesfield, Cheshire, England
[13] Univ Padua, Padua, Italy
[14] Ist Oncol Veneto IRCCS, Padua, Italy
关键词
D O I
10.1158/1538-7445.AM2018-CT038
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CT038
引用
收藏
页数:2
相关论文
共 50 条
[21]   Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial [J].
Litton, J. K. ;
Hurvitz, S. A. ;
Mina, L. A. ;
Rugo, H. S. ;
Lee, K-H ;
Goncalves, A. ;
Diab, S. ;
Woodward, N. ;
Goodwin, A. ;
Yerushalmi, R. ;
Roch, H. ;
Im, Y-H ;
Eiermann, W. ;
Quek, R. G. W. ;
Usari, T. ;
Lanzalone, S. ;
Czibere, A. ;
Blum, J. L. ;
Martin, M. ;
Ettl, J. .
ANNALS OF ONCOLOGY, 2020, 31 (11) :1526-1535
[22]   Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients [J].
Angell, Helen ;
Ros, Vidalba Rocher ;
Standifer, Nathan ;
Lai, Zhongwu ;
Gresty, Christopher ;
Delord, Jean-Pierre ;
De Jonge, Maja ;
Postel-Vinay, Sophie ;
Italiano, Antoine ;
Krebs, Matthew G. ;
Kaufman, Bella ;
Park, Yeon Hee ;
Domchek, Susan ;
Herbolsheimer, Pia ;
Hodgson, Darren .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[23]   A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation. [J].
Sun, Tao ;
Shi, Yanxia ;
Cui, Jiuwei ;
Yin, Yongmei ;
Ouyang, Quchang ;
Liu, Qiang ;
Zhang, Qingyuan ;
Chen, Yiding ;
Shao Zhimin ;
Wang, Shouman ;
Wang, Xiaojia ;
Tong, Zhongsheng ;
Zhong, Yahua ;
Yan, Min ;
Yan, Xi ;
Wang, Chuan ;
Yang, Haiyuan ;
Li, Miao ;
Xiang, Xiao ;
Xu, Binghe .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[24]   OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). [J].
Tutt, Andrew Nicholas James ;
Kaufman, Bella ;
Gelber, Richard D. ;
Mc Fadden, Eleanor ;
Goessl, Carsten Dietrich ;
Viale, Giuseppe ;
Arahmani, Amal ;
Fumagalli, Debora ;
Azim, Hatem Abdel ;
Wu, Wenting ;
Grocholewicz, Anna ;
Costantino, Joseph P. ;
Rastogi, Priya ;
Garber, Judy Ellen ;
Geyer, Charles E. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[25]   BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC) [J].
Dalvi, T. ;
Gelmon, K. A. ;
Dent, R. ;
Pegram, M. ;
Loibl, S. ;
Tazir, Y. ;
Milner, A. ;
Lewis, J. .
ANNALS OF ONCOLOGY, 2017, 28
[26]   LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation [J].
Gelmon, K. A. ;
Walker, G. P. ;
Fisher, G. V. ;
McCutcheon, S. C. .
ANNALS OF ONCOLOGY, 2018, 29
[27]   OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm) [J].
Tutt, A. ;
Kaufman, B. ;
Garber, J. ;
Gelber, R. ;
McFadden, E. ;
Goessl, C. ;
Viale, G. ;
Geyer, C. ;
Zardavas, D. ;
Arahmani, A. ;
Fumagalli, D. ;
De Azambuja, E. ;
Ponde, N. ;
Herbolsheimer, P. ;
Wu, W. ;
Constantino, J. ;
Rastogi, P. .
ANNALS OF ONCOLOGY, 2017, 28
[28]   Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation [J].
Schwartzberg, Lee S. ;
Kiedrowski, Lesli A. .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[29]   Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit? [J].
Kuemmel, S. ;
Jackisch, C. ;
Mueller, V. ;
Schneeweiss, A. ;
Klawitter, S. ;
Lux, M. P. .
ANNALS OF ONCOLOGY, 2017, 28
[30]   Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer [J].
Morganti, Stefania ;
Jin, Qingchun ;
Vincuilla, Julie ;
Buehler, Ryan ;
Ryan, Sean ;
Stokes, Samantha ;
Parker, Tonia ;
Mittendorf, Elizabeth A. ;
King, Tari A. ;
Weiss, Anna ;
Partridge, Ann H. ;
Bychkovsky, Brittany L. ;
Curigliano, Giuseppe ;
Tayob, Nabihah ;
Lin, Nancy U. ;
Garber, Judy E. ;
Tolaney, Sara M. ;
Lynce, Filipa .
NPJ BREAST CANCER, 2024, 10 (01)